시장보고서

상품코드

1553475

골수이형성증후군 약 시장 규모, 점유율, 동향 분석 리포트 : 치료별, 투여 경로별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Myelodysplastic Syndrome Drugs Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immune Treatments), By Route Of Administration, By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 - 2030

발행일: 2024년 08월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

골수이형성증후군 약 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 골수이형성증후군 약 시장 규모는 2024-2030년 CAGR 9.1%를 기록하며, 2030년에는 52억 8,000만 달러에 달할 것으로 예측됩니다.

강력한 제품 파이프라인, 고령 인구 증가, 유리한 정부 정책 등의 요인이 시장을 주도하고 있습니다.

MDS는 혈액 세포의 발생을 조절하는 하나 이상의 유전자 돌연변이로 인해 발생합니다. 이 질환의 환자는 혈소판 감소, 호중구 감소, 빈혈과 같은 임상 증상을 보입니다. 대부분의 사례(90% 이상)는 60 세 이상에서보고되었지만이 질병은 모든 연령대에서 발생할 수 있으며 여성보다 남성에게 더 많이 발생하며 MDS 사례의 약 30%는 급성 골수성 백혈병(AML)으로 전환됩니다.

면역조절제 부문은 레블리미드의 판매 호조로 MDS 치료제 시장에서 지배적인 지위를 유지할 것으로 예상됩니다. 루스파텔셉트와 아라네스프의 승인 가능성에 힘입어 항악성종양제 부문은 메틸화 억제제보다 높은 시장 점유율을 차지하며 전체 시장 확대에 크게 기여할 것으로 예상됩니다.

MDS는 분자 수준에서 매우 불균일한 질병이기 때문에 희귀한 환자군을 치료할 수 있는 새로운 약물을 개발하는 것이 중요한 과제입니다. 또한 표준 치료 패러다임의 무력화로 인한 이환율 문제와 삶의 질 저하로 인해 노인들의 삶의 질이 저하되고 있습니다.

골수이형성증후군 치료제 시장 보고서 하이라이트

줄기세포 이식이 시장을 장악하고 2023년 38.7%의 점유율을 차지할 것으로 예상됩니다. 줄기세포 이식은 손상된 골수 대신 건강한 기증자의 줄기세포를 사용합니다. 줄기세포 이식은 고용량 화학요법이나 방사선 치료로 손상된 골수를 회복시킬 수 있습니다.
경구 투여 경로는 2023년 59.5%로 가장 큰 시장 매출 점유율을 차지했습니다. 정제 및 주사와 관련된 부작용 제거와 같은 경구용 약물의 장점은 시장 성장을 가속하는 몇 가지 요인입니다.
병원 부문은 2023년 48.6%로 가장 큰 시장 매출 점유율을 차지했습니다. 만성질환의 유병률 증가로 인해 집에서 치료할 수 없는 집중 치료를 제공하는 병원이 증가하고 있습니다.
북미 골수이형성증후군 치료제 시장은 2023년 35.44%의 매출 점유율을 차지했습니다. 이러한 성장의 배경에는 노인 인구 증가와 골수이형성증후군(MDS) 증가가 있습니다.
아시아태평양의 골수이형성증후군 치료제 시장은 예측 기간 중 가장 빠른 CAGR을 나타낼 것으로 추정됩니다. 이러한 성장의 주요 요인은 노령 인구 증가, 기업 및 연구 기관의 발전입니다.

골수이형성증후군 약 시장 점유율, 지역별, 2023년 및 2030년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
라틴아메리카
- 브라질
중동 및 아프리카
- 사우디아라비아
- 아랍에미리트
- 남아프리카공화국

제8장 경쟁 구도

주요 시장 참여 기업에 의한 최근 동향과 영향 분석
기업 분류
기업 히트맵 분석
기업 개요
- Celgene Corporation
- Otsuka Pharmaceutical Co. Ltd
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Takeda Pharmaceutical Company Ltd
- Mylan NV
- Cipla Pharmaceutical Limited
- Onconova Therapeutics
- Hikma Pharmaceuticals PLC

KSA 24.09.25

Myelodysplastic Syndrome Drugs Market Growth & Trends:

The global myelodysplastic syndrome drugs market size is expected to reach USD 5.28 billion by 2030, exhibiting at a CAGR of 9.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors such as strong product pipeline, rising geriatric population, and favorable government initiatives are driving the market.

MDS is caused by mutation of one or more genes that control development of blood cells. Patients with this condition may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Although majority of cases (over 90%) are reported in people over the age of 60, the condition can occur at any age, more frequently in men than in women. About 30% of MDS cases advance to acute myeloid leukemia (AML).

The immunomodulatory drug segment is expected to retain its dominant position in the MDS drugs market due to strong sales of Revlimid. Supported by potential approvals of luspatercept and Aranesp, the anti-anemics drug segment is forecast to gain higher market share than hypomethylating agents, thus contributing significantly to the overall expansion of the market.

Developing novel drugs for the treatment of rare subsets of MDS patients is a key challenge as the disease is highly heterogeneous at the molecular level. In addition, morbidity issues and poor quality of life due to incapacitating effects of the standard of care treatment paradigms are causes of inconvenience for geriatric population.

Myelodysplastic Syndrome Drugs Market Report Highlights:

Stem cell transplant dominated the market and accounted for a share of 38.7% in 2023. Stem transplants use stem cells from healthy donors to replace damaged bone marrow. Stem cell transplant has the potential to restore the bone marrow damaged from high chemotherapy doses or from radiation therapy.
Oral route of administration accounted for the largest market revenue share of 59.5% in 2023. The advantages of oral medicines, such as tablets and the elimination of injection-associated adverse events, are a few factors driving the market growth.
The hospital segment accounted for the largest market revenue share of 48.6% in 2023. The rising prevalence of chronic diseases is driving hospitals to provide a concentrated treatment that cannot be treated at home.
North America's myelodysplastic syndromes drugs market dominated with revenue share of 35.44% in 2023. This growth is attributed to the growing geriatric population and growing incidences of myelodysplastic syndrome (MDS).
The Asia Pacific myelodysplastic syndrome drugs market is estimated to register the fastest CAGR over the forecast period. The growth is primarily attributed to the rising geriatric population and advancements by companies and research institutions.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Myelodysplastic Syndrome Drugs Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Myelodysplastic Syndrome Drugs Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Myelodysplastic Syndrome Drugs Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Myelodysplastic Syndrome Drugs Market: Product Movement Analysis, 2023 & 2030 (USD Million)
4.3. Chemotherapy
- 4.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Immune Treatments
- 4.4.1. Immune Treatments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Stem Cell Transplant
- 4.5.1. Stem Cell Transplant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Other Treatment Types
- 4.6.1. Other Treatment Types Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Myelodysplastic Syndrome Drugs Market: Application Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Myelodysplastic Syndrome Drugs Market: Route of Administration Movement Analysis, 2023 & 2030 (USD Million)
5.3. Oral
- 5.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Parenteral
- 5.4.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Myelodysplastic Syndrome Drugs Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Myelodysplastic Syndrome Drugs Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospitals
- 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Clinics
- 6.4.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Other
- 6.5.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Myelodysplastic Syndrome Drugs Market: Regional Estimates & Trend Analysis

7.1. Myelodysplastic Syndrome Drugs Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
- 7.2.1. North America Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. UK Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. China
  - 7.4.2.1. China Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Japan
  - 7.4.3.1. Japan Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. India Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
  - 7.4.5.1. South Korea Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. Australia
  - 7.4.6.1. Australia Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Saudi Arabia
  - 7.6.2.1. Saudi Arabia Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. UAE
  - 7.6.3.1. UAE Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. South Africa
  - 7.6.4.1. South Africa Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. Celgene Corporation
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Otsuka Pharmaceutical Co. Ltd
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Amgen Inc.
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Teva Pharmaceutical Industries Ltd.
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Sun Pharmaceutical Industries Limited
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Takeda Pharmaceutical Company Ltd
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Mylan N.V.
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Cipla Pharmaceutical Limited
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. Onconova Therapeutics
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Hikma Pharmaceuticals PLC
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/ Strategic Initiatives

골수이형성증후군 약 시장 규모, 점유율, 동향 분석 리포트 : 치료별, 투여 경로별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Myelodysplastic Syndrome Drugs Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immune Treatments), By Route Of Administration, By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 - 2030

골수이형성증후군 약 시장의 성장과 동향 :

골수이형성증후군 치료제 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 개요

제3장 골수이형성증후군 약 시장의 변수, 동향, 범위

제4장 골수이형성증후군 약 시장 : 치료별 추정·동향 분석

제5장 골수이형성증후군 약 시장 : 용도별 추정·동향 분석

제6장 골수이형성증후군 약 시장 : 최종 용도별 추정·동향 분석

제7장 골수이형성증후군 약 시장 : 지역별 추정·동향 분석